Advancements and Controversies in Alzheimer's Treatment

This chapter examines the progression of neurodegeneration in Alzheimer's patients and the impact of both traditional and new drug treatments. It highlights the approval and subsequent withdrawal of aducanumab, explores newer medications like licanumab and denunumab, and discusses the challenges of clinical trials and regulatory science. The conversation delves into the complexities of treatment metrics and the implications for patients, emphasizing the ongoing debate surrounding the effectiveness of these advancements.